MEDICATIONS TO TREAT MULTIPLE SCLEROSIS: THE PRESENT AND THE FUTURE

Download full text PDF
Issue: 
9
Year: 
2015

A. Volkov (1), Candidate of Medical Sciences; Professor I. Krylova (2), MD 1 -City Polyclinic Sixty-Nine, Moscow 2 -I.M. Sechenov First Moscow State Medical University

The paper considers basic medications to treat multiple sclerosis and their mechanisms of action.

Keywords: 
multiple sclerosis
disease-modifying drugs for the treatment of multiple sclerosis



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Aktas O., Kury P., Kieseier B., Hartung H.P. Fingolimod is a potential novel therapy for multiple sclerosis // Nat. Rev. Neurol. – 2010; 6: 373–82.
  2. Bielekova B., Howard T., Packer A. et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis // Arch. Neurol. – 2009; 66: 483–9.
  3. Bielekova B., Becker B. Monoclonal antibodies in MS: mechanisms of action // Neurology. – 2010; 74: 31–40.
  4. Berger J. Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies // Am. J. Manag. Care. – 2011; 17 (Suppl. 5): 146–53.
  5. Brinkmann V. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system // Br. J. Pharmacol. – 2009; 158: 1173–82.
  6. Cadavid D., Wolansky L., Skurnick J. et al. Efficacy of treatment of MS with IFNβ-1b or glatiramer acetate by monthly brain MRI in the BECOME study // Neurology. – 2009; 72 (23): 1976–83.
  7. Calabresi P., Goodin D., Jeffery D. et al. Efficacy and Safety of Fingolimod Versus Placebo: Primary Outcomes from the Phase 3 FREEDOMS II Study in Patients with Relapsing-Remitting Multiple Sclerosis / Lyon, France: ECTRIMS, 2012.
  8. Calabresi P., Kieseier B., Arnold D. et al. Clinical Efficacy and Safety of Peginterferon Beta-1a in Relapsing Multiple Sclerosis: Data from the Pivotal Phase 3 ADVANCE Study / San Diego, USA: AAN, 2013.
  9. Comi G., Jeffery D., Kappos L. et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis // N. Engl. J. Med. – 2012; 366: 1000–9.
  10. Deogracias R., Yazdani M., Dekkers M. et al. Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome // Proc. Natl. Acad. Sci. USA. – 2012; 109: 14230–5.
  11. Ellwardt E., Zipp F. Molecular mechanisms linking neuroinflammation and neurogeneration in MS // Exp. Neurol. Epub. – 2014; 262 (Pt. A): 8–17.
  12. Ford C., Johnson K., Lisak R. et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients // Mult. Scler. – 2006; 12 (3): 309–20.
  13. Gold R., Giovannoni G., Selmaj K. et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial // Lancet. – 2013; 381: 2167–75.
  14. Gorelik L., Lerner M., Bixler S. et al. Anti-JC virus antibodies: implications for PML Risk Stratification // Ann. Neurol. – 2010; 68: 295–303.
  15. Hu Y., Turner M., Shields J. et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model // Immunology. – 2009; 128: 260– 70.
  16. Irvine K., Blakemore W. Remyelination protects axons from demyelination-associated axon degeneration // Brain. – 2008; 131: 1464–77.
  17. Kappos L., Radue E., O’Connor P. et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis // N. Engl. J. Med. – 2010; 362: 387–401.
  18. Kappos L., Li D., Calabresi P. et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial // Lancet. – 2011; 378: 1779–87.
  19. Kim S., Kim W., Li X. et al. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? // Mult. Scler. – 2012; 18 (10): 1480–3.
  20. Mancardi G., Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis // Lancet Neurol. – 2008; 7: 626–36.
  21. Martinelli V., Cocco E., Capra R. et al. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone // Neurology. – 2011; 77: 1887–95.
  22. Meissner M., Valesky E., Kippenberger S. et al. Dimethyl fumarate – only an anti-psoriatic medication? // J. Dtsch. Dermatol. Ges. – 2012; 10: 793–801.
  23. Metz L., Sabuda D., Hilsden R. et al. Gastric tolerance of high-dose pulse in multiple sclerosis // Neurology. – 1999; 53: 2093–6.
  24. Mi S., Miller R., Lee X. et al. LINGO-1 negatively regulates myelination by oligodendrocytes // Nat. Neurosci. – 2005; 8: 745–51.
  25. Mikol D., Barkhof F., Chang P. et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the Rebif vs Glatiramer Acetate in Relapsing MS Disease (REGARD) study): a multicentre, randomised, parallel, open-label trial // Lancet Neurol. – 2008; 7 (10): 903–14.
  26. Nickerson M., Marrie R. The multiple sclerosis relapse experience: patient-reported outcomes from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry // BMC Neurol. – 2013; 13: 119.
  27. Noseworthy J., Lucchinetti C., Rodriguez M. et al. Multiple sclerosis // N. Engl. J. Med. – 2000; 343 (13): 938–52.
  28. Noseworthy J., Wolinsky J., Lublin F. et al. Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results North American Linomide Investigators // Neurology. – 2000; 54: 1726–33.
  29. Nylander A., Hafler D. Multiple sclerosis // J. Clin. Invest. – 2012; 122 (4): 1180–8.
  30. O’Connor P., Goodman A., Kappos L. et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis // Neurology. – 2011; 76: 1858–65.
  31. O’Connor P., Wolinsky J., Confavreux C. et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis // N. Engl. J. Med. – 2011; 365: 1293–303.
  32. O’Connor P., Wolinsky J., Confavreux C. et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis // N. Engl. J. Med. – 2012; 365: 1293–303.
  33. Ontaneda D., Rae-Grant A. Management of acute exacerbations in multiple sclerosis //Ann. Indian Acad. Neurol. – 2009; 12: 264–72.
  34. Polman C., Reingold S., Banwell B. et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria // Ann. Neurol. – 2011; 69 (2): 292–302.
  35. Rae-Grant A., Eckert N., Bartz S. et al. Sensory symptoms of multiple sclerosis: a hidden reservoir of morbidity // Mult. Scler. – 1999; 5: 179–83.
  36. Ross A., Ben-Zacharia A., Harris C. et al. Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone // Front. Neurol. – 2013; 4 (21): 1–12.
  37. Saccardi R., Mancardi G., Solari A. et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life // Blood. – 2005; 105: 2601–7.
  38. Saidha S., Eckstein C., Calabresi P. New and emerging disease modifying therapies for multiple sclerosis // Ann. NY Acad. Sci. – 2012; 1247: 117–37.
  39. Schwid S., Panitch H. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: A multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis // Clin. Ther. – 2007; 29 (9): 2031–48.
  40. Scott L. Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis // CNS Drugs. – 2013; 27 (11): 971–88.
  41. Sellebjerg F., Barnes D., Filippini G. et al. EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses // Eur. J. Neurol. – 2005; 12: 939–46.
  42. Sellebjerg F., Frederiksen J., Nielsen P. et al. Double-blind, randomized, placebocontrolled study of oral, high-dose methylprednisolone in attacks of MS // Neurology. – 1998; 51: 529–34.
  43. Sladkova V., Mares J., Lubenova B. et al. Drug-induced systemic lupus erythematosus in interferon beta-1b therapy // Neurol. Endocrinol. Lett. – 2011; 32 (1): 4–6.
  44. Thone J., Ellrichmann G., Seubert S. et al. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor // Am. J. Pathol. – 2012; 180: 267–74.
  45. Wee Yong V., Chabot S., Stuve O. et al. Interferon beta in the treatment of multiple sclerosis: mechanisms of action // Neurology. – 1998; 51: 682–9.